- Severe local tissue necrosis will occur if there is extravasation during administration (See PRECAUTIONS). Epirubicin must not be given by the intramuscular or subcutaneous route.
- Myocardial toxicity, manifested in its most severe form by potentially fatal congestive heart failure (CHF), may occur either during therapy with epirubicin or months to years after termination of therapy. The probability of developing clinically evident CHF is estimated as approximately 0.9% at a cumulative dose of 550 mg/m2, 1.6% at 700 mg/m2, and 3.3% at 900 mg/m2. In the adjuvant treatment of breast cancer, the maximum cumulative dose used in clinical trials was 720 mg/m2. The risk of developing CHF increases rapidly with increasing total cumulative doses of epirubicin in excess of 900 mg/m2; this cumulative dose should only be exceeded with extreme caution. Active or dormant cardiovascular disease, prior or concomitant radiotherapy to the mediastinal/pericardial area, previous therapy with other anthracyclines or anthracenediones, or concomitant use of other cardiotoxic drugs may increase the risk of cardiac toxicity. Cardiac toxicity with ELLENCE may occur at lower cumulative doses whether or not cardiac risk factors are present.
- Secondary acute myelogenous leukemia (AML) has been reported in patients with breast cancer treated with anthracyclines, including epirubicin. The occurrence of refractory secondary leukemia is more common when such drugs are given in combination with DNA-damaging antineoplastic agents, when patients have been heavily pretreated with cytotoxic drugs, or when doses of anthracyclines have been escalated. The cumulative risk of developing treatment-related AML or myelodysplastic syndrome (MDS), in 7110 patients with breast cancer who received adjuvant treatment with epirubicin-containing regimens, was estimated as 0.27% at 3 years, 0.46% at 5 years and 0.55% at 8 years.
- Dosage should be reduced in patients with impaired hepatic function (see DOSAGE AND ADMINISTRATION).
- Severe myelosuppression may occur.
- Epirubicin should be administered only under the supervision of a physician who is experienced in the use of cancer chemotherapeutic agents.
ELLENCE Injection (epirubicin hydrochloride injection) is an anthracycline cytotoxic agent, intended for intravenous administration.
ELLENCE Injection is indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.
Media Articles Related to Ellence (Epirubicin)
4th Annual Pharma 2016: Sales & Marketing Excellence Forum, 24th - 25th November 2016, Shanghai
Source: Conferences News From Medical News Today [2016.11.07]
Big Pharma companies in China are looking for growth in 2016 to rise up to the challenges to the industry's approach to sales and marketing.
Novel compounds arrested epilepsy development in mice
Source: Epilepsy News From Medical News Today [2016.07.25]
A team led by Nicolas Bazan, MD, PhD, Boyd Professor and Director of LSU Health New Orleans' Neuroscience Center of Excellence, has developed neuroprotective compounds that may prevent the...
Saying Nighty-Night to Breast Cancer Sleep Disturbance
Source: Medscape Hematology-Oncology Headlines [2016.12.02]
Acupuncture improved sleep better than did gabapentin in breast cancer survivors with hot flashes.
Medscape Medical News
Bisphosphonates and Fracture Risk in Women With Breast Cancer
Source: Medscape Orthopaedics Headlines [2016.12.01]
Could long-term oral bisphosphonate use paradoxically increase fracture risk among postmenopausal women with breast cancer?
What's New at World's Biggest Breast Cancer Meeting
Source: Medscape Hematology-Oncology Headlines [2016.11.30]
The San Antonio Breast Cancer Symposium will feature a diverse set of headlining studies.
Medscape Medical News
Published Studies Related to Ellence (Epirubicin)
Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node-positive breast cancer. [2011.08.20]
PURPOSE: The Docetaxel Epirubicin Adjuvant (DEVA) trial evaluated the efficacy and toxicity of incorporating docetaxel after epirubicin to create a sequential anthracycline-taxane regimen in early breast cancer... CONCLUSION: These results suggest, within a relatively small trial, that substitution of docetaxel for epirubicin for the last three cycles of chemotherapy results in improved outcome in postmenopausal women with node-positive, early breast cancer compared with six cycles of epirubicin monotherapy.
Epirubicin and paclitaxel with G-CSF support in first line metastatic breast cancer: a randomized phase II study of dose-dense and dose-escalated chemotherapy. [2011.07]
An increased dose-intensity can be achieved by either higher dose of chemotherapy per cycle (dose-escalation) or by shortening the interval between cycles (dose-dense). This multicenter randomized phase II study assessed the efficacy and safety of two different approaches: epirubicin 110 mg/m(2) combined with paclitaxel 200 mg/m(2) every 21 days and epirubicin 75 mg/m(2) combined with paclitaxel 175 mg/m(2) every 10 days, both supported with G-CSF...
Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel. [2011.04.27]
CONCLUSION: TP53 and CHEK2 mutations were associated with lack of response to epirubicin monotherapy. In contrast, TP53 mutations and MDM2 309G allele status conferred poor disease-specific survival among patients treated with primary paclitaxel but not epirubicin monotherapy.
A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study. [2011.04.12]
BACKGROUND: To evaluate activity and tolerability of two anthracycline-containing regimens as first-line treatment for anthracycline-naive relapsed breast cancer patients... CONCLUSIONS: Both anthracycline- containing regimens evaluated in the present study seem to be active and with a satisfactory tolerability in anthracycline-naive relapsed breast cancer patients.
Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study. [2011.02.15]
BACKGROUND: This randomised phase II study compared the activity and safety of the combination docetaxel (D)/epirubicin (EPI) with the conventional treatment D/prednisone (P) in advanced castrate-resistant prostate cancer (CRPC) patients... CONCLUSION: The treatment of advanced CRPC with weekly D combined with weekly EPI was feasible and tolerable, and led to superior PFS than the treatment with 3-weekly D and oral P.
Clinical Trials Related to Ellence (Epirubicin)
Epirubicin and Vinorelbine in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer [Terminated]
RATIONALE: Drugs used in chemotherapy, such as epirubicin and vinorelbine, work in different
ways to stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing. Giving epirubicin together with vinorelbine may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving epirubicin together with
vinorelbine works in treating patients with stage II, stage III, or stage IV breast cancer.
Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer [Active, not recruiting]
This phase I clinical trial studies the side effects and the best dose of dinaciclib when
given together with epirubicin hydrochloride (epirubicin) in patients with metastatic
(cancer that has spread to other parts of the body) triple-negative breast cancer.
Dinaciclib is designed to stop cancer cells from dividing into new cancer cells. Epirubicin
is designed to block the way cancer cells grow and divide and may slow or stop cancer cells
from spreading throughout the body. Researchers want to find out what is the highest
tolerable dose of the experimental drug dinaciclib that can be given in combination with
epirubicin in patients with metastatic triple negative breast cancer.
A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors [Completed]
This is an open-label, four-arm, Phase I, dose escalation study to evaluate the safety and
tolerability and to determine the optimal tolerated regimen (OTR) of pazopanib in
combination with epirubicin or doxorubicin in patients with advanced solid tumors. Patients
will be enrolled in cohorts of 3 to receive escalating doses of pazopanib and epirubicin or
doxorubicin. Dose escalation schemas for each study arm are described in the protocol. For
each arm, the OTR will be defined as the highest dose combination of the agents where no
more than one out of six patients experiences a dose-limiting toxicity. Twelve additional
patients in each arm will be studied with the OTR to evaluate toxicity and pharmacokinetics.
This will allow an assessment of potential drug-drug interactions. Antitumor activity will
be assessed using RECIST criteria.
Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer [Completed]
In this trial we will evaluate ABI-007 with gemcitabine and epirubicin, utilizing the
biweekly pegfilgrastim support, in order to further improve upon the effectiveness and
favorable toxicity of this triplet.
Predictors for Response to Dose-dense Docetaxel and Epirubicin Breast Cancer [Recruiting]
Molecular markers predicting response to dose dense chemotherapy with epirubicin and
docetaxel in sequence for locally advanced breast cancer
Principal Investigator Per E Lonning, Professor, Section of Oncology, Department of Medicine
Collaborators. Dept of Surgery - Responsible: Turid Aas, Consultant Surgeon Dept of
Molecular Biology - Responsible: Professor Johan Lillehaug Dept of Anatomy and Cellular
Biology - Responsible: Professor Rolf Bjerkvig
Participants. Dept of Oncology Gun Anker, Consultant Oncologist Stephanie Geisler,
Consultant Oncologist Jurgen Geisler, Consultant Oncologist
Type of Study Phase II, Translational research
Scientific aims: Addressing factors predicting response to dose intensive epirubicin
followed by docetaxel sequential therapy
Treatment regimen: epirubicin 60 mg/m2 on a 2 weekly basis x 4 followed by docetaxel 100
mg/m2 2-weekly x 4.
Patients: Breast cancer patients below 65 years of age suffering from large (>4 cm largest
diameter, non-inflammatory and / or N2-N3) primary breast cancer.
Clinical aim: Assessing responsiveness to this dose intensive regimen.
Number of patients to be enrolled: 60 - 100
Reports of Suspected Ellence (Epirubicin) Side Effects
Disease Progression (2),
Oesophageal Carcinoma (2),
Orthostatic Hypotension (1),
Pulmonary Embolism (1),
Loss of Consciousness (1),
Cardio-Respiratory Arrest (1),
Pleural Effusion (1),
Myocardial Infarction (1), more >>
Page last updated: 2016-12-02